|(R)-N6-丙基-4,5,6,7-四氢苯并噻唑-2,6-二胺二盐酸盐|CsnPharm

CAS No.: 104632-27-1

Dexpramipexole 2HCl/右旋普拉克索二盐酸盐 Catalog No. CSN17422

Synonyms: (R)-Pramipexole dihydrochloride;R-(+)-Pramipexole dihydrochloride;KNS-760704 dihydrochloride

Dexpramipexole 2HCl is the HCl form of Dexpramipexole which is a non-ergoline dopamine agonist for treatment of parkinson's disease and restless leg syndrome.Dexpramipexole is an (R)-(+) optical enantiomer of pramipexole.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Dexpramipexole (Dihydrochloride), an orally bioavailable synthetic aminobenzothiazole, showed an excellent safety profile and was coincidentally noted to significantly decrease absolute eosinophil counts (AECs) in a phase 3 trial for amyotrophic lateral sclerosis. Dexpramipexole appears promising as a GC-sparing (glucocorticoid) agent without apparent toxicity in a subset of subjects with GC-responsive HESs (Hypereosinophilic syndromes)^[3]. Dexpramipexole increased mitochondrial ATP production in cultured neurons or glia and reduces energy failure, prevents intracellular Ca2+ overload and affords cytoprotection when cultures are exposed to OGD (oxygen-glucose deprivation). Post-ischaemic treatment with dexpramipexole, at doses consistent with those already used in ALS (amyotrophic lateral sclerosis) patients, reduced brain infarct size and ameliorated neuroscore in mice subjected to transient or permanent MCAo (middle cerebral artery occlusion)^[4]. Moreover, patch-clamp recordings in rat hippocampal neurons revealed that Dexpramipexole dose-dependently inhibited (IC50 of 814 nM) the IA current, a rapidly-inactivating K+ current that negatively regulates neuronal excitability as well as cognition and memory processes. Dexpramipexole counteracted both scopolamine-induced spatial memory loss in rats challenged in Morris Water Maze test and memory retention in rats undergoing Novel Object Recognition^[5]. Dexpramipexole treatment produced profound eosinophil-lowering in peripheral blood and nasal polyp tissue^[6].
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01048229	Early-stage Parkinson's Diseas... more >>e Collapse <<	Phase 4	Terminated(recruitment)	-	-
NCT00721279	-	-	Completed	-	-
NCT02660060	Healthy	Not Applicable	Completed	-	Indonesia ... more >> PT Equilab International Jakarta, Indonesia, 12430 Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 3.5180 mL
- 17.5902 mL
- 35.1804 mL
- 5 mM
- 0.7036 mL
- 3.5180 mL
- 7.0361 mL
- 10 mM
- 0.3518 mL
- 1.7590 mL
- 3.5180 mL

技术信息

CAS号

104632-27-1

储存条件

粉末: Inert atmosphere,Room Temperature

液体: -20°C:3-6 月 -80°C:12月

分子式

C10H19Cl2N3S

运输

蓝冰

分子量

284.25

别名

(R)-Pramipexole dihydrochloride;R-(+)-Pramipexole dihydrochloride;KNS-760704 dihydrochloride;(R)-Pramipexole 2HCl;KNS-760704;SND-919CL2X;(R)-Pramipexole (hydrochloride);Dexpramipexole;(+)-Pramipexole;R-Pramipexole;右旋普拉克索二盐酸盐

溶解度

DMSO	95.0 mg/mL (334.2 mM) warming
Water	100.0 mg/mL (351.8 mM) warming

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01048229	Early-stage Parkinson's Diseas... more >>e Collapse <<	Phase 4	Terminated(recruitment)	-	-
NCT00721279	-	-	Completed	-	-
NCT02660060	Healthy	Not Applicable	Completed	-	Indonesia ... more >> PT Equilab International Jakarta, Indonesia, 12430 Collapse <<
NCT00140218	Amyotrophic Lateral Sclerosis	Phase 1 Phase 2	Completed	-	United States, Pennsylvania ... more >> David Lacomis MD Pittsburgh, Pennsylvania, United States United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908 Collapse <<
NCT00600873	Amyotrophic Lateral Sclerosis	Phase 1 Phase 2	Completed	-	United States, Virginia ... more >> University of Virginia Charlottesville, Virginia, United States, 22908 Collapse <<
NCT00596115	-	-	-	-	-
NCT00721279	-	-	Completed	-	-
NCT00893841	Bipolar Depression	Phase 2	Completed	-	United States, California ... more >> Affiliated Research Institute San Diego, California, United States, 92108 United States, Washington Eastside Therapeutic Resource Kirkland, Washington, United States, 98033 Canada, Alberta Dr. P. Chokka Edmonton, Alberta, Canada, T6L 6W6 Canada, British Columbia Penticton Regional Penticton, British Columbia, Canada, V2A 4M4 Copeman Neuroscience Centre Vancouver, British Columbia, Canada, V6Z 2L4 Canada, Nova Scotia AK Munshi Medical Inc. Sydney, Nova Scotia, Canada, B1S 2E8 Canada, Ontario Regional Mental Health Care - London London, Ontario, Canada, N6A 4H1 Canada, Quebec Hôpital Louis-H.Lafontaine Montreal, Quebec, Canada, H1N 3M5 Canada Clinique Marie Fitzbach Quebec, Canada, G1R 2W8 Collapse <<
NCT01074463	Healthy	Phase 1	Completed	-	United States, North Dakota ... more >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Collapse <<
NCT01074450	-	-	Completed	-	-
NCT01074463	-	-	Completed	-	-
NCT01074450	Healthy	Phase 1	Completed	-	United States, North Dakota ... more >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Collapse <<

Dexpramipexole 2HCl/右旋普拉克索二盐酸盐 Catalog No. CSN17422

靶点选择性

请登录您的专属账户

确认信息